These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 36977797)

  • 1. Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.
    Rose KM; Huelster HL; Meeks JJ; Faltas BM; Sonpavde GP; Lerner SP; Ross JS; Spiess PE; Grass GD; Jain RK; Kamat AM; Vosoughi A; Wang L; Wang X; Li R
    Nat Rev Urol; 2023 Jul; 20(7):406-419. PubMed ID: 36977797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
    Zhang R; Zang J; Xie F; Zhang Y; Wang Y; Jing Y; Zhang Y; Chen Z; Shahatiaili A; Cai MC; Zhao Z; Du P; Jia S; Zhuang G; Chen H
    J Urol; 2021 Oct; 206(4):873-884. PubMed ID: 34061567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature.
    Green EA; Li R; Albiges L; Choueiri TK; Freedman M; Pal S; Dyrskjøt L; Kamat AM
    Eur Urol Oncol; 2021 Dec; 4(6):893-903. PubMed ID: 33975782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis.
    Liu H; Chen J; Huang Y; Zhang Y; Ni Y; Xu N; Zhao F; Tang Y; Liu H; Sun G; Shen P; Liu Z; Huang J; Liao B; Zeng H
    Int J Surg; 2024 Jun; 110(6):3923-3936. PubMed ID: 38573063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.
    Agarwal N; Pal SK; Hahn AW; Nussenzveig RH; Pond GR; Gupta SV; Wang J; Bilen MA; Naik G; Ghatalia P; Hoimes CJ; Gopalakrishnan D; Barata PC; Drakaki A; Faltas BM; Kiedrowski LA; Lanman RB; Nagy RJ; Vogelzang NJ; Boucher KM; Vaishampayan UN; Sonpavde G; Grivas P
    Cancer; 2018 May; 124(10):2115-2124. PubMed ID: 29517810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [High-throughput molecular analysis of urothelial carcinoma: potential clinical applications].
    Todenhöfer T; Miernik A; Seiler R
    Aktuelle Urol; 2019 Feb; 50(1):84-93. PubMed ID: 30731506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomics in upper tract urothelial carcinoma.
    Kammerer-Jacquet SF; Mathieu R; Peyronnet B; Rioux-Leclercq N; Bensalah K
    Curr Opin Urol; 2017 Jan; 27(1):35-40. PubMed ID: 27584028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-specific targeted analysis of circulating tumour DNA in plasma is feasible and may be a potential biomarker in UTUC.
    Mu N; Jylhä C; Axelsson T; Sydén F; Brehmer M; Tham E
    World J Urol; 2023 Dec; 41(12):3421-3427. PubMed ID: 37721600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma.
    Nakano K; Koh Y; Yamamichi G; Yumiba S; Tomiyama E; Matsushita M; Hayashi Y; Wang C; Ishizuya Y; Yamamoto Y; Kato T; Hatano K; Kawashima A; Ujike T; Fujita K; Kiyotani K; Katayama K; Yamaguchi R; Imoto S; Imamura R; Nonomura N; Uemura M
    Cancer Sci; 2022 May; 113(5):1830-1842. PubMed ID: 35293110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma.
    Nordentoft I; Lindskrog SV; Birkenkamp-Demtröder K; Gonzalez S; Kuzman M; Levatic J; Glavas D; Ptashkin R; Smadbeck J; Afterman D; Lauterman T; Cohen Y; Donenhirsh Z; Tavassoly I; Alon U; Frydendahl A; Rasmussen MH; Andersen CL; Lamy P; Knudsen M; Polak P; Zviran A; Oklander B; Agerbæk M; Jensen JB; Dyrskjøt L
    Eur Urol; 2024 Oct; 86(4):301-311. PubMed ID: 38811314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative recurrence detection using individualized circulating tumor DNA in upper tract urothelial carcinoma.
    Tamura D; Abe M; Hiraki H; Sasaki N; Yashima-Abo A; Ikarashi D; Kato R; Kato Y; Maekawa S; Kanehira M; Takata R; Maejima K; Sasagawa S; Fujita M; Suzuki Y; Nakagawa H; Iwaya T; Nishizuka SS; Obara W
    Cancer Sci; 2024 Feb; 115(2):529-539. PubMed ID: 38083992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
    Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
    Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From Detection to Cure - Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer.
    Linscott JA; Miyagi H; Murthy PB; Yao S; Grass GD; Vosoughi A; Xu H; Wang X; Yu X; Yu A; Zemp L; Gilbert SM; Poch MA; Sexton WJ; Spiess PE; Li R
    Curr Oncol Rep; 2024 Aug; 26(8):945-958. PubMed ID: 38837106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report.
    Blumendeller C; Boehme J; Frick M; Schulze M; Rinckleb A; Kyzirakos C; Kayser S; Kopp M; Kelkenberg S; Pieper N; Bartsch O; Hadaschick D; Battke F; Stenzl A; Biskup S
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33431630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.
    Shohdy KS; Villamar DM; Cao Y; Trieu J; Price KS; Nagy R; Tagawa ST; Molina AM; Sternberg CN; Nanus DM; Mosquera JM; Elemento O; Sonpavde GP; Grivas P; Vogelzang NJ; Faltas BM
    Br J Cancer; 2022 Feb; 126(3):430-439. PubMed ID: 35046520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic profiling of Chinese patients with urothelial carcinoma.
    Yang B; Zhao X; Wan C; Ma X; Niu S; Guo A; Wang J; Wang J; Sun D; Jiao S
    BMC Cancer; 2021 Feb; 21(1):162. PubMed ID: 33588785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liquid biopsy in urothelial carcinoma: Detection techniques and clinical applications.
    Wu S; Li R; Jiang Y; Yu J; Zheng J; Li Z; Li M; Xin K; Wang Y; Xu Z; Li S; Chen X
    Biomed Pharmacother; 2023 Sep; 165():115027. PubMed ID: 37354812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder.
    Rink M; Schwarzenbach H; Riethdorf S; Soave A
    World J Urol; 2019 Sep; 37(9):1785-1799. PubMed ID: 30367205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Pathology of Urothelial Carcinoma.
    Al-Ahmadie H; Netto GJ
    Clin Lab Med; 2024 Jun; 44(2):181-198. PubMed ID: 38821640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial.
    Zang J; Zhang R; Jin D; Xie F; Shahatiaili A; Wu G; Zhang Y; Zhao Z; Du P; Jia S; Chen H; Zhuang G
    J Pathol; 2023 Oct; 261(2):198-209. PubMed ID: 37584165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.